Expiring federal contract · order under a contract vehicle
75N93019F00131 — University Of Alabama At Birmingham
Department of Health and Human Services · National Institutes of Health
- Contract / PIID
- 75N93019F00131
- Incumbent
- University Of Alabama At Birmingham
- Incumbent UEI
- YND4PLMC9AN7
- Current end date
- April 30, 2027
- Potential total value
- $8,820,523
- Obligated
- $8,820,523
- NAICS
- 541711 — Research and Development in Biotechnology
- PSC
- AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
- Set-aside
- Not stated
- Start date
- August 23, 2019
- Place of performance
- AL
- Award type
- DELIVERY ORDER
Source: USASpending.gov award record, last checked November 18, 2026. Place of performance as reported by USASpending.
What the contract covers
THIS TASK ORDER IS FOR THE DEVELOPMENT OF A PROTOCOL, CLINICAL TRIAL IMPLEMENTATION, CLOSEOUT AND ANALYSIS OF A PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY OF RMENB+OMV NZ (BEXSERO, GSK) IN PREVENTING N. GONORRHOEAE INFECTION.
Likely rebid window (estimate)
- Sources Sought / RFI: about Apr 2026 – Oct 2026 (6–12 months before the end date)
- RFP: about Dec 2026 – Feb 2027 (2–4 months before the end date)
Between the estimated Sources Sought and RFP windows.
This is an order under contract vehicle HHSN272201300012I. Orders are usually not competed on their own: the next order may be placed under the same vehicle.
Estimated from the current end date using typical federal recompete timing. Agencies set their own schedules, and contracts are often extended. This is not a published solicitation date.
Track this recompete free
- Change history: 1 recorded change to the end date, value or incumbent. Sign up to see each one.
- Alerts: get an email when the end date moves or the follow-on is posted.
- Contacts: the buying office and small-business contacts for this agency.
Other contracts expiring at Department of Health and Human Services (NAICS 541711)
- 75N93022F00001 — University Of North Carolina At Chapel Hill · ends November 30, 2026 · $1.7M
- 75N93019F00132 — The Emmes Company, LLC · ends December 31, 2026 · $174K
- HHSN27500007 — Lundquist Institute For Biomedical Innovation At Harbor-ucla Medical Center · ends December 31, 2026 · $12M
- HHSO100201600017C — Dnae Group Holdings Limited · ends December 31, 2026 · $43M
- 75N93024F00002 — University Of Texas Medical Branch At Galveston · ends January 17, 2027 · $3.3M
- HHSO100201600009C — Cerus Corporation · ends March 31, 2027 · $185M
- HHSN275201700002C — The Emmes Company, LLC · ends May 28, 2027 · $66M
- 75N93024F00001 — Trustees Of Tufts College · ends July 10, 2027 · $823K
- HHSO100201700020C — Regeneron Pharmaceuticals INC · ends September 25, 2027 · $279M
- HHSO100201700012C — Merck Sharp & Dohme LLC · ends September 27, 2027 · $236M